FDA approves Alkermes' Lybalvi for schizophrenia and bipolar

Alkermes said that it is expecting to make Lybalvi available for patients in the fourth quarter of 2021 - News - PharmaTimes

Related Keywords

, Alkermes , Drug Administration , Negative Syndrome Scale , Richard Pops , Lybalvi , Schizophrenia , Bipolari Disorder , எதிர்மறை நோய்க்குறி அளவு , ரிச்சர்ட் பாப்ஸ் ,